A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
A phase 2 trial of A166 in HER2-positive breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07299825 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 40 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-09-20. Interventions recorded: A166.
Similar pages
not linked directly; found by shared links- TrialA Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
Shares A166, Sichuan Kelun-Biotech, HER2-positive breast cancer.
- TrialSKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Study of KL590586 in Patients With Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Study of SKB571 in Patients With Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB103 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB565 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB118 Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.